Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus


The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord Genuity analyst Sumant Kulkarni presented a list of key catalysts for companies in his coverage universe, with those involving neurological disorder drugs dominating the list.



from Biotech News